The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Quinn, N. B., Januszewski, A. S., Brazionis, L., O'Connell, R. L., Aryal, N. R., O’Day, J., Scott, R. S., Mitchell, P. L. R., Jenkins, A. J., KEECH, A. C., et al. (2022) · Internal Medicine Journal · doi:10.1111/imj.15733 · Cited by 4
Wang, X., Liu, X., Tzekov, R. T., Yu, C., Yang, J., Feng, Y., Wu, Y., Xu, Y., Li, S., & Li, W. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s420178 · Cited by 4
Aung, N. L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0038 · Cited by 4
Reverse Translational Study of Fenofibrate's Observed Effects in Diabetes‐Associated Retinopathy
Farris, R., & Price, E. (2016) · Clinical and Translational Science · doi:10.1111/cts.12412 · Cited by 4
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 4
Conceptos Actuales de la Terapia Con Insulina.
Montero, G. J., Barakat, M. V., & Solórzano, M. L. C. (2022) · Revista Ciencia y Salud Integrando conocimientos · doi:10.34192/cienciaysalud.v6i3.416 · Cited by 4
Mitsiou, E. K., Athyros, V. G., Karagiannis, A. I., & Mikhailidis, D. P. (2012) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401206010028 · Cited by 4
Cardiovascular Disease and Glycemic Treatment
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb11 · Cited by 4
Do statins reduce microvascular complications in diabetes?
Preiss, D. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70177-9 · Cited by 4
Screening for Diabetic Retinopathy in Youth-Onset Diabetes
Chew, E. Y. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.02.001 · Cited by 4
Das, A. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2342_19 · Cited by 4
Wu, X., Yan, Y., Li, Y., Fan, Y., Li, L., Tsui, C., Liu, K., Liang, X., Huang, W., Hu, A., et al. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04139-z · Cited by 3
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 4
Walia, S., Morya, A. K., Khullar, S., Aggarwal, S., & Kaur, R. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.109231 · Cited by 3
Macrovascular and microvascular complications of type 2 diabetes mellitus
Мамедов, М. Н., Друк, И. В., Arabidze, G. G., & Akhundova, H. R. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20242708194 · Cited by 3
Marinho, L. L., Ribeiro, M. L., Lawler, P. R., Iatan, I., Godoy, L. C., Rached, F. H., & Maranhão, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01292-0 · Cited by 3
Zambon, A., Gentile, L., Galimberti, F., Manzato, E., Giaccari, A., Sesti, G., Belfiore, A., Norata, G. D., Temporelli, P. L., Frulloni, L., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104214 · Cited by 3
Garberg, G., Boström, K. B., Hjerpe, P., Ayala, M. N., Adrian, M. L., & Andersson, T. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005356 · Cited by 5
Diet and Supplements in the Prevention and Treatment of Eye Diseases
Mares, J. A., Millen, A. E., & Meyers, K. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00019-6 · Cited by 3
Morein, J., Uvarov, A., Spaic, T., Mahon, J. L., HRAMIAK, I. M., & Liu, S. (2021) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2021.01.002 · Cited by 3
Akimoto, H., Takahashi, Y., & Asai, S. (2021) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.20-00259 · Cited by 3
Brod, M. I., Waldman, L. T., Sparre, T., & Busk, A. K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221079396 · Cited by 3
Atherogenic Dyslipemia Working Group of the Spanish Society of Atherosclerosis and the European Expert Group (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.002 · Cited by 3
Nguyen, H., Kha, R., Gopinath, B., Mitchell, P. L. R., & Liew, G. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-089518 · Cited by 3
Tatti, P. (2010) · Clinical ophthalmology · doi:10.2147/opth.s10273 · Cited by 3
Diabetes update: Your guide to the latest ADA standards.
Johnson, E. L., Warren, F., SKOLNIK, N., & Shubrook, J. H. (2016) · PubMed · Cited by 3
Stefanowicz-Rutkowska, M. M., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2020) · Medicina · doi:10.3390/medicina56060255 · Cited by 3
Evaluating the Risk Factors of Development and Progression of Diabetic Retinopathy: A Review Study
Rasoulinejad, S. A. (2022) · Shiraz E-Medical Journal · doi:10.5812/semj.117171 · Cited by 6
Current approaches to the management of diabetic retinopathy
Demidova, T. Y., & Trakhtenberg, Y. A. (2014) · Diabetes Mellitus · doi:10.14341/dm20143122-128 · Cited by 3
Objectifs du contrôle de la glycémie
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.036 · Cited by 3
Farnier, M. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.37 · Cited by 3
Qi, S., Wang, C., Zhang, Y., Cheng, Y., Wang, S., & Zhao, Y. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.11.002 · Cited by 3
Myths in the Treatment of Type 2 Diabetes
Wade, M. T., & Rindone, J. P. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31820159aa · Cited by 3
Meng, X., Zhang, Y., Kong, Q., Lv, Y., Hu, H., Chen, T., & Tang, Z. (2019) · Traditional Medicine and Modern Medicine · doi:10.1142/s2575900019500101 · Cited by 3
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac125.66516667 · Cited by 3
Public willingness to receive COVID-19 vaccine in Saudi Arabia
Alamri, A., Alshahrani, N. A. M., Bakita, A. A. A., Alqahtani, A. S., Alshahrani, J. H. A., & Alshahrani, M. S. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94092 · Cited by 3
Diabetic retinopathy and other ocular complications
Tan, G. S. W., & Wong, T. Y. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch61 · Cited by 3
Mixed messages on systemic therapies for diabetic retinopathy – Authors' reply
Ismail-Beigi, F., Craven, T. E., GENUTH, S. M., Hramiack, I., & Karl, D. M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61986-1 · Cited by 3
A Brand Theory of Trademark LawPreprint
Desai, D. R. (2010) · SSRN Electronic Journal · doi:10.2139/ssrn.1585327 · Cited by 3
Small Dense LDL Tied to Diabetic Retinopathy-Similarity to Atherosclerosis
Hirano, T. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed174 · Cited by 3
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.62 · Cited by 3
Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression
Silva, P. S., & Aiello, L. P. (2024) · NEJM Evidence · doi:10.1056/evide2400205 · Cited by 3
Impact of Dyslipidemia Medications on the Prevalence of Diabetic Retinopathy Among a Large US Cohort
Chadalavada, S. H., Shaia, J. K., Russell, M. W., Talcott, K. E., & Singh, R. P. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20231017-01 · Cited by 2
Niewiem, A., Broniarek, K., & Michalska‐Małecka, K. (2025) · Diagnostics · doi:10.3390/diagnostics15151873 · Cited by 2
Risikomodifikation durch Ernährung und Nahrungsergänzungsmittel bei diabetischen Augenerkrankungen
Chronopoulos, A., Garzone, D., & Finger, R. P. (2025) · Die Ophthalmologie · doi:10.1007/s00347-025-02328-1 · Cited by 2
Hemoglobin A1c time-in-range, mortality, and diabetes complications in older adults with diabetes
Conlin, P. R., Prentice, J. C., Mohr, D. C., Zhang, L., Li, D., Pleasants, E. A., Nelson, R. E., Vupputuri, S. X., & Nichols, G. A. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005188 · Cited by 2
Kakihara, S., Zhuang, K., Busza, A. M., & Fawzi, A. A. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.15.3 · Cited by 2
Large language models for primary care ophthalmic education: a systematic review
Li, S., Wang, X., Chen, Y., Tian, M., Lin, P., Lai, M., & Jiang, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1810098 · Cited by 2
Relevanz von Fibraten in der Diabetestherapie
Klose, G. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0393-0 · Cited by 2
Ceramide-mediation of diffusion in supported lipid bilayers
Hossain, M., & Blanchard, G. J. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105090 · Cited by 2
Delaying and preventing diabetic retinopathy
Thomas, R. (2021) · Practical Diabetes · doi:10.1002/pdi.2360 · Cited by 2
Frequency of Diabetic Retinopathy among known Diabetics at District Level Teaching Hospital
Ghaffar, Z., Butt, Z., Shah, S. M. A., Tarar, S. H., & Afzal, M. (2022) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v38i3.1361 · Cited by 2
Tasdika, T. E., Choudhury, N., Hossain, Q. M. I., & Kabir, Y. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01142-9 · Cited by 2
G‐estimation of structural nested mean models for interval‐censored data using pseudo‐observations
Tanaka, S., Brookhart, M. A., & Fine, J. P. (2023) · Statistics in Medicine · doi:10.1002/sim.9838 · Cited by 2
Microvascular complications: Diabetic eye disease
Sultan, S., & Memon, R. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00025-5 · Cited by 2
Diabetic retinopathy and choroidopathy: Pathophysiology, imaging findings, and treatment updates
Silpa‐archa, S., Tadarati, M., Chotcomwongse, P., & Ruamviboonsuk, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15583-3.00016-0 · Cited by 2
Jin, G., Ma, Y., Zheng, D., Jin, L., Young, C. A., Shen, Y., Tan, Y., Jin, J., Zhang, X., Wu, Y., et al. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2023-324930 · Cited by 2
Bantounou, M. A., Nahar, T. A. K., Plascevic, J., Kumar, N. S., Nath, M., Myint, P. K., & Philip, S. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.07.012 · Cited by 3
Ong, K. L., Januszewski, A. S., Francis, H., O’Connell, R. L., Mangani, A., Li, L., Colman, P. G., SULLIVAN, D. R., Scott, R. S., Jenkins, A. J., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112080 · Cited by 2
Cross-prevalence of large and small vessels disease in T2DM: overview from a Belgian academic centre
Lurquin, F. O., Petit, E. L., Ahn, S. A., Rousseau, M. F., & Hermans, M. P. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2524239 · Cited by 2
Epidemiology, Risk Factors, and Pathophysiology of Diabetic Retinopathy
Bhagat, N., & Zarbin, M. A. (2014) · Springer eBooks · doi:10.1007/978-3-642-54503-0_1 · Cited by 2
Prophylactic Medical Treatment of Diabetic Retinopathy
Kakehashi, A., Ota, A., Toyoda, F., Kinoshita, N., Yamagami, H., Obata, H., Matsumoto, T., Tsuji, J., Dobashi, Y., Yeo, W., et al. (2012) · InTech eBooks · doi:10.5772/29964 · Cited by 3
Evaluación de la aplicación de las guías de hipertensión y diabetes en un programa de crónicos
Morales, J. C. Á., Bareño, A., Castro, J., & Rojas, C. M. (2014) · Revista Med · doi:10.18359/rmed.1176 · Cited by 3
Romero‐Aroca, P. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2010.12.011 · Cited by 2
Potential drug interventions for diabetic retinopathy
Shen, Q., Wu, J. Z., & Wong, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.08.018 · Cited by 2
Innovations thérapeutiques dans la rétinopathie diabétique
Massin, P. (2011) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2011.04.007 · Cited by 2
Should we start all patients with diabetic retinopathy on fenofibrates?
Koshy, J., Koshy, J., Thomas, S., Kaur, G., & Mathew, T. (2013) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.120012 · Cited by 2
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2011) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.07.003 · Cited by 2
Ismail‐Beigi, F., Lombardero, M. S., Escobedo, J., GENUTH, S. M., Green, J., Massaro, E. M., Mooradian, A. D., Ovalle, F., Whitehouse, F. W., & Zonszein, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.01.006 · Cited by 2
2009 World Congress on the Insulin Resistance Syndrome: Cardiovascular Disease Concepts
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb07 · Cited by 2
Dyslipidemia aterogenna w codziennej praktyce — interdyscyplinarny konsensus polskich ekspertów
Szymański, F. M., Filipiak, K. J., Wożakowska−Kapłon, B., Szaflik, J. P., Dzida, G. J., Kurkowska‐Jastrzębska, I., Narkiewicz, K., Łazicka-Gałecka, M., Gil, R. J., & Gumprecht, J. (2017) · Folia Cardiologica · doi:10.5603/fc.a2016.0106 · Cited by 2
Update on the Pharmacologic Agents for Dyslipidemia
Lee, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.269 · Cited by 2
Regier, E. E., Gao, H. X., & Close, K. L. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12328 · Cited by 2
Parashar, H., Shastri, D. A., Goel, D. S., Thakur, D. S., Sitaraman, C., & Sharma, D. G. (2016) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2016.i06.10 · Cited by 2
Diabetes-Related Microvascular Complications: What Every Nurse Practitioner Needs to Know
Egan, E. A. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.08.030 · Cited by 3
Current Treatment Recommendations
Stewart, M. W. (2017) · Springer eBooks · doi:10.1007/978-981-10-3509-8_6 · Cited by 2
Effect of Monocular Intravitreal Anti-Vascular Endothelial Growth Factor Injection on the Fellow Eye
El-Moniem, S. R. A., El-Enin, A. I. A., & Rashwan, A. H. (2019) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2019.64850 · Cited by 2
Cocoa olein glycerolysis with lipase Candida antarctica in a solvent free system
Zamorano, L. S., Magaña, P. C., Cisneros, E. G., Martínez, A. V., & Martín, L. F. (2020) · Grasas y Aceites · doi:10.3989/gya.0794191 · Cited by 2
Lee, C.-H., Tseng, P.-L., Chang, W., Chen, Y., & Chiu, T.-T. (2021) · Archives of Medical Science · doi:10.5114/aoms/133705 · Cited by 2
Stock, J. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.013 · Cited by 2
Al-Muhannadi, M., Al-Karbi, K., Amran, H. A. A., Alsharafi, A. F. M., Alabbas, O. T., Al-Marri, K., & Salem, M. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94094 · Cited by 2
Nanoparticles as drug delivery agents for managing diabetic retinopathy
Mukherjee, S., Panda, P., & Mishra, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-820557-0.00014-x · Cited by 2
Genomic profile of diabetic retinopathy in a north indian cohort
Sikka, R., Raina, P., Soni, R., Gupta, H., & Bhanwer, A. J. S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08772-z · Cited by 2
Shi, L., Ye, X., Lü, M., Wu, E. Q., Sharma, H., Thomason, D., Zhang, M., Wang, Y., & Fonseca, V. A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0122-2 · Cited by 2
Progression of retinopathy in persons with type 2 diabetes: new data, same conclusions?
Klein, B. E. K. (2010) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.983 · Cited by 2
Patient Management in Clinical Practice
Fung, T. H. M., & Amoaku, W. M. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-43063-4_3 · Cited by 2
Fibrate Use in the United States and Canada
Lim, L. S. (2011) · JAMA · doi:10.1001/jama.2011.946 · Cited by 2
Mixed messages on systemic therapies for diabetic retinopathy
Sauerhoefer, S., Lammert, A., Köppel, H., Hammes, H., & Krämer, B. K. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61985-x · Cited by 2
American Diabetes Association Postgraduate Meetings—2011
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-1557 · Cited by 2
Management of Hyperlipidemia in 2015
Feingold, K. R. (2015) · The Endocrine Society eBooks · doi:10.1210/mtp4.9781936704941.ch24 · Cited by 2
WITHDRAWN: Targets for Glycemic Control
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.04.008 · Cited by 4
RetractedRetinopathy in Diabetic Pregnancy
Hasan, J., & Chew, E. Y. (2017) · doi:10.1002/9781119043805.ch21 · Cited by 2
Promoting Eye Health in Low-Resource Areas by “Doing More with Less”
Congdon, N. G., & He, M. (2018) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2018496 · Cited by 2
Fenofibrate: a guide to its use in dyslipidaemia
Keating, G. M., & McKeage, K. (2012) · Drugs & Therapy Perspectives · doi:10.2165/11608570-000000000-00000 · Cited by 1
Diabetic Retinopathy in Youth-Onset Type 2 Diabetes Mellitus
Richardson, E., & Farrell, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55138-0.00008-5 · Cited by 1
Combined lipid-lowering therapy
Karásek, D. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.169 · Cited by 1
The pattern of diabetic foot and its complications in Albaha, Saudi Arabia
Alghamdi, A., Alghamdi, A. G., Alghamdi, A. A. M., Aldokhi, M. A., Alzahrani, A. M., AlGhamdi, E. S., Alzahrani, A. A., & Alghamdi, R. A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.940105 · Cited by 1
Zhang, Y., Han, H., Lv, J., & Chu, L. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0431 · Cited by 1
Diabetes Mellitus Associated Progressive Neurovascular Retinal Injury
Sinclair, S. H. (2023) · Springer eBooks · doi:10.1007/978-3-031-25779-7_18 · Cited by 1
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
